期刊文献+

雌激素受体α基因PvuⅡrs2234693多态性与乳癌发病风险的meta分析

PvuⅡrs2234693 polymorphisms in estrogen receptor α and breast cancer risk:a meta-analysis
下载PDF
导出
摘要 目的:探讨雌激素受体( ER)α基因PvuⅡrs2234693位点多态性与乳癌发病风险之间的关系。方法:将2002年至2012年国内外发表的ERα基因PvuⅡrs2234693多态性与乳癌关系相关的文献进行检索,并进行异质性检验,计算OR值(95%CI)。结果:符合纳入标准的共有14篇文献,累计乳癌病例10755例,对照17074例。与野生纯合基因型TT相比,CC突变基因型异质性检验P=0.03,OR(95%CI)为0.91(0.81~1.02);CT杂合型及CC+CT联合型的异质性检验P分别为0.57、0.44,OR(95%CI)分别为0.96(0.90~1.02)、0.94(0.89~1.00)。结论:未发现ERα基因PvuⅡrs2234693位点多态性与乳癌发病风险之间的相关性。 Aim:To explore the relationship between PvuⅡrs2234693 polymorphisms in estrogen receptor α( ERα) and risk of breast cancer occurrence .Methods: All literatures related to PvuⅡrs2234693 polymorphisms in ERαand breast cancer which published openly between 2002 and 2012 were reviewed .Heterogeneity test for each research data was performed and OR(95%CI) was analyzed.Results:There were 14 literatures conformed to the inclusion criteria .A total of 10 755 breast cancer cases and 17 074 controls were included .The meta-analysis showed that compared with the wild-type homozygous TT, the P of heterogeneity test for CC variant genotype was 0.03, and OR(95%CI) was 0.91(0.81-1.02).The P of heterogeneity test for CT heterozygous and CC +CT joint type was 0.57, 0.44, and OR(95%CI) was 0.96(0.90-1.02), 0.94(0.89-1.00).Conclusion: No relationship between the genotype of PvuⅡrs2234693 poly-morphisms in ERαand risk of breast cancer occurrence is found .
出处 《郑州大学学报(医学版)》 CAS 北大核心 2013年第5期588-591,共4页 Journal of Zhengzhou University(Medical Sciences)
基金 国家自然科学基金资助项目81202278
关键词 雌激素受体Α 多态性 乳癌 META分析 estrogen receptor α polymorphism breast cancer meta-analysis
  • 相关文献

参考文献20

  • 1Forouzanfar MH, Foreman KJ, Delossantos AM, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis [J]. Lancet, 2011, 378 (9801) :1461.
  • 2Jemal A, Bray F, Center MM, et al. Global cancer statis- tics [J]. CA CancerJClin, 2011, 61(2) :69.
  • 3Colditz GA. Estrogen, estrogen plus progestin therapy,and risk of breast cancer [ J ]. Clin Cancer Res, 2005, 11 (2 Pt 2) :909s.
  • 4Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer[J]. N EnglJMed, 2006, 354(3) :270.
  • 5Shin A, Kang D, Nishio H, et al. Estrogen receptor alpha gene polymorphisms and breast cancer risk [ J ]. Breast Cancer Res Treat, 2003, 80( 1 ) :127.
  • 6Han W, Kang D, Lee KM, et al. Full sequencing analysis of estrogen receptor-alpha gene polymorphism and its asso- ciation with breast cancer risk [ J ]. Anticancer Res, 2003, 23(6C) :4703.
  • 7Dunning AM,Healey CS, Baynes C, et al. Association of ESR1 gene tagging SNPs with breast cancer risk[ J]. Hum Mol Genet, 2009, 18(6) :1131.
  • 8Sonestedt E,Ivarsson MI, Harlid S,et al. The protective asso- ciation of high plasma enterolacton with breast cancer is rea- sonably robust in women with polymorphisms in the estrogen receptor alpha and beta genes[J]. J Nutr,2009,139(5):993.
  • 9Gonzdlez-Mancha R, Galdn JJ, Crespo C, et al. Analysis of the ER alpha germline Pvu Ⅱ marker in breast cancer risk[J]. Med Sci Monit, 2008, 14(3):CR136.
  • 10Gonzdlez-Zuloeta Ladd AM, V6squez AA, Vasguez AA, et al. Estrogen receptor alpha polymorphisms and postm- enopausal breast cancer risk [ J ]. Breast Cancer Res Treat, 2008, 107(3) :415.

二级参考文献23

共引文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部